Natalizumab treatment during pregnancy in multiple sclerosis—clinical and bioethical aspects of an ongoing debate

Multiple sclerosis at the crossroads of scientific evidence and clinical translation

“…Natalizumab is an approved treatment for relapsing-remitting MS, for which safety during pregnancy has not been formally proven. Klaus Berek and coworkers' case report and review of the literature (Innsbruck, Austria) addresses the evidence for prenatal risks in the natalizumabexposed offspring vs. the maternal risks due to rebound activity after natalizumab cessation [2]. The second case report concerns the rare but relevant differential diagnoses of atypical, inflammatory CNS lesions and the clinical utility of MR spectroscopy.…”